EPA Supplementation and HDL Particle Heterogeneity in Statin-Treated Coronary Artery Disease Patients

This randomized trial enrolled 100 statin-treated CAD patients and examined the effect of EPA supplementation on HDL particle size distribution and heterogeneity — measured by gel filtration chromatography — as a potential mechanism for cardiovascular risk reduction beyond LDL-C lowering.

EPA supplementation shifted HDL particle distribution toward larger, more cardioprotective HDL2 particles and away from small HDL3 particles, compared with controls. The EPA group also showed improvements in EPA/AA ratio and oxidized LDL. HDL heterogeneity — reflecting the relative proportion of HDL subfractions — shifted in a direction associated with better reverse cholesterol transport function.

HDL’s cardiovascular protective role is primarily mediated through reverse cholesterol transport — the removal of cholesterol from peripheral tissues (including arterial walls) and its delivery to the liver for excretion. HDL particle size and functionality are increasingly recognized as more clinically relevant than simple HDL-C concentration; multiple failed HDL-raising drug trials (torcetrapib, dalcetrapib, niacin) demonstrated that raising HDL-C does not uniformly improve outcomes.

Whether EPA supplementation’s observed effects on HDL particle distribution translate to clinical cardiovascular event reduction is not established from this study, which was powered for biomarker endpoints rather than events.

We rate the evidence limited. A small RCT demonstrating EPA supplementation’s effect on HDL particle heterogeneity in statin-treated CAD patients — mechanistically interesting but insufficient to establish clinical outcome benefit.